Key Takeaways
- • Breakthrough Properties completed a $3 billion fundraise, more than double its $1.5 billion target, marking the largest dedicated life sciences real estate fund ever raised (excluding portfolio recapitalizations), according to CBRE and JLL.
- • The joint venture between real estate developer Tishman Speyer and Bellco Capital will deploy capital across U.S. and European life sciences campuses serving biotechnology, pharmaceuticals, medical technology, genetics, and medical device companies.
- • Fund proceeds will support both existing operational projects and new development initiatives, positioning the vehicle to capture sustained demand from the high-growth biotech and biopharma sectors seeking dedicated research and development facilities.
- • Co-founder and CEO Dan Belldegrun attributed the oversubscription to validated market thesis, citing two years of demonstrated life sciences sector growth as both a financial opportunity and a public health imperative for supporting innovation in life-saving treatments.
Summary
Breakthrough Properties, a real estate partnership between mogul Tishman Speyer and Bellco Capital, has closed a $3 billion fundraise for dedicated life sciences real estate development and acquisition. The capital commitment more than doubled the fund's initial $1.5 billion target and represents the largest dedicated real estate vehicle in the life sciences sector on record, excluding recapitalizations of existing portfolios, as confirmed by CBRE and JLL.
The fund specializes in acquiring and developing purpose-built campuses and facilities for the life sciences ecosystem, including biotechnology companies, pharmaceutical manufacturers, medical technology firms, genetics research operations, and medical equipment producers. The two-year fundraising period reflects sustained institutional appetite for life sciences real estate, driven by accelerating biotech innovation cycles and pharmaceutical sector consolidation requiring specialized laboratory and research infrastructure.
Breakthrough will deploy proceeds across two tranches: financing existing projects already in operation and funding new development initiatives spanning the United States and Europe. This geographic diversification positions the fund to capitalize on regional biotech hubs while maintaining exposure to emerging innovation clusters. The oversubscription signals confidence among institutional investors in the structural demand drivers within the life sciences sector.
Dan Belldegrun, Breakthrough's co-founder and CEO, attributed the fundraise success to validated sector fundamentals, stating that "the rapidly growing field of life sciences is the correct investment, not only financially, but also in terms of public health around the world." He emphasized Breakthrough's mission to create operational environments enabling biotechnology innovators and researchers to develop life-saving treatments while providing long-term business support services. The fund's strategy reflects a broader institutional shift toward real assets backing innovation-driven sectors with structural tailwinds.
The fund specializes in acquiring and developing purpose-built campuses and facilities for the life sciences ecosystem, including biotechnology companies, pharmaceutical manufacturers, medical technology firms, genetics research operations, and medical equipment producers. The two-year fundraising period reflects sustained institutional appetite for life sciences real estate, driven by accelerating biotech innovation cycles and pharmaceutical sector consolidation requiring specialized laboratory and research infrastructure.
Breakthrough will deploy proceeds across two tranches: financing existing projects already in operation and funding new development initiatives spanning the United States and Europe. This geographic diversification positions the fund to capitalize on regional biotech hubs while maintaining exposure to emerging innovation clusters. The oversubscription signals confidence among institutional investors in the structural demand drivers within the life sciences sector.
Dan Belldegrun, Breakthrough's co-founder and CEO, attributed the fundraise success to validated sector fundamentals, stating that "the rapidly growing field of life sciences is the correct investment, not only financially, but also in terms of public health around the world." He emphasized Breakthrough's mission to create operational environments enabling biotechnology innovators and researchers to develop life-saving treatments while providing long-term business support services. The fund's strategy reflects a broader institutional shift toward real assets backing innovation-driven sectors with structural tailwinds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.